Please assess the completion status of the following clinical trial:

Trial Title: The Luveris In Vitro Fertilization Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 30 women under 38 years old at time of signing Informed Consent Form.~2. Evidence of hypothalamic amenorrhea (irregular menses and FSH and LH \<5 mIU/mL), uncorrected hyperprolactinemia (prolactin levels 10% above the upper limit of normal) or iatrogenic hypothalamic hypogonadism secondary to GnRHa suppression.~3. In good general health off of current medications which may confound response to study medications except GnRHa (Lupron Depot).~4. Desire to seek pregnancy actively during the study period.~5. A normal uterine cavity must have been confirmed by either hysteroscopy or hydrosonogram within two years of entering the study.~6. A semen analysis on the male partner deemed adequate for IVF by the attending physician within the past year or donor sperm available for insemination.~7. Only one treatment cycle per patient will be studied.~Exclusion Criteria:~1. uncorrected thyroid disease.~2. heart disease (New York Heart Association Class II or higher).~3. a history of, or suspected cervical, endometrial, or breast cancer. A normal Pap smear result within the last 24 months will be required.~4. enrolled into other studies that require medications, limit sex, or otherwise prevent compliance with the protocol at the same time.~5. to take other medications known to affect reproduction.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Luveris Fixed dose (Type: ACTIVE_COMPARATOR): Participants in this arm will take Gonal F® and the same dose of Luveris® throughout the cycle. Their dose of Gonal F® will be adjusted throughout the cycle based on their response to the medication. The Luveris® dose will remain constant throughout.
- Luveris increasing dose (Type: EXPERIMENTAL): Patients assigned to this group will gradually reduce the Gonal F® dose while increasing the Luveris® dose during the cycle, which more closely mimics the natural menstrual cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).